AYTU BIOPHARMA, INC. — Income Charts
2 years of history · ending 2025-06-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$66M
Cost of Revenue
$21M
Gross Profit
$46M
R&D
$1M
SG&A
—
D&A
$200K
Operating Income
$-8M
EBITDA
$-8M
Interest Expense
$4M
Other Income/Expense
$-2M
Pretax Income
$-14M
Tax Provision
$437K
Net Income
$-14M
Gross Margin
69.0%
Operating Margin
-11.8%
Net Margin
-20.4%
Effective Tax Rate
-3.2%
Deferred Tax Assets
$252K
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$137M
Tax Credit Carryforwards
$2M
NOL Carryforwards
$517M
ETR (Continuing Operations)
-3.2%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.2%
Operating Lease Cost
—
Revenue YoY Variation
1.8%
Income YoY Variation
-392.0%